Mark Kirschbaum
2022
In 2022, Mark Kirschbaum earned a total compensation of $523.8K as Senior Vice President and Chief Medical Officer at Cyclacel Pharmaceuticals, a 34% decrease compared to previous year.
Compensation breakdown
| Bonus | $97,644 |
|---|---|
| Salary | $381,500 |
| Other | $44,699 |
| Total | $523,843 |
Kirschbaum received $381.5K in salary, accounting for 73% of the total pay in 2022.
Kirschbaum also received $97.6K in bonus and $44.7K in other compensation.
Rankings
In 2022, Mark Kirschbaum's compensation ranked 4,261st out of 5,717 executives tracked by ExecPay. In other words, Kirschbaum earned more than 25.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,261 out of 5,717 | 26th |
Division Manufacturing | 2,400 out of 3,111 | 23rd |
Major group Chemicals And Allied Products | 1,163 out of 1,410 | 18th |
Industry group Drugs | 1,091 out of 1,311 | 17th |
Industry Pharmaceutical Preparations | 796 out of 957 | 17th |
Source: SEC filing on April 28, 2023.
Kirschbaum's colleagues
We found two more compensation records of executives who worked with Mark Kirschbaum at Cyclacel Pharmaceuticals in 2022.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021